BioSpace News Archive

Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), today announced the closing of its previously announced public offering of an aggregate of 11,819,172 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock purchase warrants, at a public offering price of $0.525 per share (or pre-funded warrant) and accompanying warrants.

This week, a federal judge in California issued a landmark decision siding with the California Stem Cell Treatment Center (CSCTC) in a lawsuit brought by the U.S. Food and Drug Administration, ruling that Cell Surgical Network’s innovative surgical procedure that uses patients’ stem cells to treat a range of medical conditions does not fall under the FDA’s regulatory jurisdiction.

Avid Bioservices, Inc. (NASDAQ:CDMO), today announced the appointment of Pramthesh (Prem) Patel, Ph.D., as vice president, process development for its mammalian cell business.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, announced two senior management promotions, as well as the addition of a new member to its leadership team.

Ultragenyx Pharmaceutical Inc. announced that Eric Crombez, Chief Medical Officer, Gene Therapy, will participate in a Rare Disease Panel at Citi’s 17th Annual BioPharma Conference on Wednesday, September 7, 2022, at 11:20 AM ET.

Foghorn® Therapeutics Inc., a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, announced management’s participation in upcoming investor conferences in September.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted an equity award on September 1, 2022 that was approved by the Compensation Committee of its Board of Directors under Company’s 2022 Inducement Equity Incentive Plan, as a material inducement to employment to one individual hired by Acutus in August 2022.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that its collaboration with Dr. Iñaki Sanz at Emory University has led to a publication in Nature.

Paratek Pharmaceuticals, Inc. announced that on August 31, 2022, the Company granted stock options to one new employee of the Company.

Femasys Inc. (NASDAQ: FEMY), today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference being held on a hybrid basis September 12-14, 2022, and in-person at the Lotte New York Palace Hotel in New York, NY.